<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570258</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 2004-19</org_study_id>
    <nct_id>NCT00570258</nct_id>
  </id_info>
  <brief_title>Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy</brief_title>
  <official_title>Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind study of fulvestrant plus erlotinib versus
      fulvestrant plus placebo for subjects with metastatic breast cancer whose disease progression
      after first line hormonal therapy.

        1. To obtain preliminary estimates of the magnitude and variability of the efficacy of
           fulvestrant in combination with erlotinib in this subject population, and

        2. To obtain historically up-to-date estimates of the magnitude and variability of the
           efficacy of fulvestrant as the sole active agent in this subject population.

      The measure of efficacy for both primary objectives will be time to progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind study of fulvestrant plus erlotinib versus
      fulvestrant plus placebo for subjects with metastatic breast cancer whose disease progressed
      after first line hormonal therapy.

        -  Total number of subjects planned for the trial is 130 subjects, that is, approximately
           65 subjects in each arm.

        -  Subjects will be randomized to receive fulvestrant/erlotinib (arm A) or
           fulvestrant/placebo (arm B) and stratified based on accrual center.

        -  The study is a parallel-arm double-blind study, with fulvestrant + placebo on the
           monotherapy arm, and fulvestrant + erlotinib on the combination arm.

        -  The primary variable outcome is time to progression.

        -  Subjects whose metastatic disease was diagnosed more than 12 months after completing
           adjuvant hormonal therapy are eligible to this study if their breast cancer is
           hormone-receptor-positive and after disease progression on first line hormonal therapy
           in the metastatic setting. Subjects may have received no more than one line of
           chemotherapy. While receiving one line of hormonal therapy in the metastatic setting is
           a requirement, receiving chemotherapy is not, and one line of chemotherapy in the
           metastatic setting would not exclude these subjects from the trial. Subjects who had a
           recurrence while on adjuvant hormonal treatment or within 12 months of completion of the
           adjuvant hormonal treatment are also eligible without the need to receive first line
           hormonal therapy in the metastatic setting.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA approved higher dose of study drug. Dose used in protocol lower than SOC - enrollment
    stopped, those on treatment were given option to opt out.
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Progression-free Survival</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>This will be defined as the date from randomization onset to first documented occurrence of PD. Death will be regarded as a progression event in those subjects who die before disease progression. Subjects without documented objective progression at the time of the final analysis will be censored at the date of their last tumor assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Either Complete Response or Partial Response</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>evaluate response rate and the clinical benefit of fulvestrant alone or in combination with erlotinib</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fulvestrant: 250 mg IM Q 4 weeks
Placebo: 150 mg PO QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fulvestrant: 250 mg IM Q 4 weeks
Erlotinib: 150 mg PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant: 250 mg IM Q 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150 mg PO QD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>250 mg IM Q 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 150 mg PO QD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must sign a written consent.

          2. Subjects must have estrogen- and/or progesterone-receptor-positive histologically
             confirmed adenocarcinoma of the breast with recurrent or metastatic carcinoma of the
             breast.

          3. Baseline measurements and evaluations of involved sites should be performed as close
             as possible to study entry, but must be within 4 weeks prior to randomization.

          4. Subjects fulfilling one of the following criteria are eligible to participate in the
             study: Subjects with measurable disease as per RECIST criteria. This is defined as at
             least one lesion that can be accurately measured in at least one dimension (longest
             diameter to be recorded) as over 20 mm with conventional technique or as over 10 mm
             with spiral CT scan or MRI. Subjects with bone lesions, lytic or mixed (lytic +
             sclerotic), in the absence of measurable disease as defined by RECIST criteria. The
             lytic component of at least one bone lesion should measure 20 mm with conventional
             techniques or 10 mm with spiral CT scan or MRI. At least one bone lesion satisfying
             these criteria must be outside any previously irradiated area.

          5. All subjects must be postmenopausal females defined by:

        Prior bilateral oophorectomy OR No menstrual period for 12 months or longer. If age 55
        years or less and on tamoxifen within the prior 6 months, must have an estradiol level in
        the postmenopausal range.

        Exclusion Criteria:

        1. Subjects must not have had more than 1 prior chemotherapy regimen for metastatic disease
        and no chemotherapy within 3 weeks prior to randomization. 2. No concurrent chemotherapy is
        allowed while on protocol therapy. Subjects whose adjuvant hormonal therapy was
        discontinued more than 12 months ago must have had only 1 prior hormonal therapy for
        metastatic disease. Subjects who relapsed while receiving adjuvant hormonal therapy or less
        than 12 months after completing adjuvant hormonal therapy may be enrolled directly in the
        trial.

        3. No prior therapy with an estrogen receptor down-regulator (e.g. fulvestrant).
        Non-protocol concurrent hormonal therapy is not allowed. Subjects must not have had prior
        therapy with agents that target EGFR. Previous, but not concomitant, therapy with
        trastuzumab (Herceptin) is allowed. Subjects must not receive trastuzumab (Herceptin)
        within 3 weeks prior to randomization.

        4. Subjects must have ECOG performance status of 0, 1, or 2. 5. Subjects must have adequate
        hematologic, hepatic, and renal function defined by the following within 4 weeks prior to
        randomization: Neutrophils &gt; 1500/mm3 and platelets over 100,000/mm3 Total Bilirubin under
        1.25 x Institutional upper limit of normal SGPT (ALT) and SGOT (AST) under 2.5 x
        Institutional upper limit of normal if no demonstrable liver metastases or under 5 x
        Institutional upper limit of normal in the presence of liver metastases Calculated
        creatinine clearance over 30ml/min using the following formula: Ccr = (140 - age in years)
        times (weight in kgs) times 0.085 72 x serum creatinine in mg/dL INR, PT and PTT under 1.5
        x Institutional upper limit of normal.

        6. Subjects must not be receiving therapy with anticoagulants or have other
        contraindication to IM injections.

        7. Subjects must be age over 18 years. 8. Subjects must not have a history of central
        nervous system metastasis. 9. Subjects may receive concurrent radiation therapy to painful
        sites of bony disease or areas of impending fracture as long as the radiation therapy is
        initiated prior to study entry and sites of measurable disease outside the radiation
        therapy port are available to follow.

        10. Subjects must not take the following medications while enrolled in this trial:
        ketoconazole, erythromycin, verapamil.

        11. Subjects age less than 55 years must not be receiving LHRH agonists or antagonists
        within 3 months prior to randomization.

        12. Subjects who have an ocular inflammation or infection should be fully treated before
        entry into the trial.

        13. Subjects with a neuropathic keratopathy or diabetes or those with anterior basement
        membrane disease must be advised of the need for frequent ophthalmologic exams.

        14. Subjects who continue to wear contact lenses must be advised that they have an
        increased risk of ocular events. The decision to wear contact lenses should be discussed
        with the patient's treating oncologist and ophthalmologist.

        15. Subjects must not suffer from medical or psychiatric conditions that would interfere
        with protocol compliance, the ability to provide informed consent, or assessment of
        response or anticipated toxicities.

        16. Subjects must be disease-free of prior invasive malignancies for over 5 years with the
        exception of curatively-treated basal cell or squamous cell carcinoma of the skin or
        carcinoma in situ of the cervix.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issam Makhoul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NEA Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands oncology Group</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <results_first_submitted>July 6, 2018</results_first_submitted>
  <results_first_submitted_qc>January 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fulvestrant Plus Placebo</title>
          <description>Fulvestrant: 250 mg IM Q 4 weeks
Placebo: 150 mg PO QD
Fulvestrant: 250 mg IM Q 4 weeks
Placebo: Placebo 150 mg PO QD</description>
        </group>
        <group group_id="P2">
          <title>Fulvestrant Plus Erlotinib</title>
          <description>Fulvestrant: 250 mg IM Q 4 weeks
Erlotinib: 150 mg PO QD
Fulvestrant: Fulvestrant: 250 mg IM Q 4 weeks
erlotinib: 150 mg PO QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Early termination due to a change in drug FDA approval.</participants>
                <participants group_id="P2" count="0">Early termination due to a change in drug FDA approval.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Early termination due to a change in drug FDA approval. No subject completed study. No data analysis was completed.</population>
      <group_list>
        <group group_id="B1">
          <title>Fulvestrant Plus Placebo</title>
          <description>Fulvestrant: 250 mg IM Q 4 weeks
Placebo: 150 mg PO QD
Fulvestrant: 250 mg IM Q 4 weeks
Placebo: Placebo 150 mg PO QD</description>
        </group>
        <group group_id="B2">
          <title>Fulvestrant Plus Erlotnib</title>
          <description>Fulvestrant: 250 mg IM Q 4 weeks
Erlotinib: 150 mg PO QD
Fulvestrant: Fulvestrant: 250 mg IM Q 4 weeks
erlotinib: 150 mg PO QD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progression-free Survival</title>
        <description>This will be defined as the date from randomization onset to first documented occurrence of PD. Death will be regarded as a progression event in those subjects who die before disease progression. Subjects without documented objective progression at the time of the final analysis will be censored at the date of their last tumor assessment.</description>
        <time_frame>through study completion, an average of 3 years</time_frame>
        <population>Early termination due to a change in drug FDA approval. No subject completed study. No data analysis was completed. No data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant Plus Placebo</title>
            <description>Fulvestrant plus placebo: Fulvestrant will be given on day 1 by intramuscular (IM) injection into your buttock muscle(s) then every 28 days. In addition, placebo will be given as a pill, which will be taken by mouth once a day, about the same time of day every day, one hour before or two hours after a meal.</description>
          </group>
          <group group_id="O2">
            <title>Fulvestrant Plus Erlotinib</title>
            <description>Fulvestrant plus erlotinib: Fulvestrant will be given on day 1 by intramuscular (IM) injection into your buttock muscle(s) then every 28 days. In addition, erlotinib will be given as a pill, which will be taken by mouth once a day, about the same time of day every day, one hour before or two hours after a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression-free Survival</title>
          <description>This will be defined as the date from randomization onset to first documented occurrence of PD. Death will be regarded as a progression event in those subjects who die before disease progression. Subjects without documented objective progression at the time of the final analysis will be censored at the date of their last tumor assessment.</description>
          <population>Early termination due to a change in drug FDA approval. No subject completed study. No data analysis was completed. No data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Either Complete Response or Partial Response</title>
        <description>evaluate response rate and the clinical benefit of fulvestrant alone or in combination with erlotinib</description>
        <time_frame>through study completion, an average of 3 years</time_frame>
        <population>Early termination due to a change in drug FDA approval. Outcome measures not computed on collected data because data would not be statistically relevant. No data analysis was completed. No data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant Plus Placebo</title>
            <description>Fulvestrant: 250 mg IM Q 4 weeks
Placebo: 150 mg PO QD
Fulvestrant: 250 mg IM Q 4 weeks
Placebo: Placebo 150 mg PO QD</description>
          </group>
          <group group_id="O2">
            <title>Fulvestrant Plus Erlotinib</title>
            <description>Fulvestrant: 250 mg IM Q 4 weeks
Erlotinib: 150 mg PO QD
Fulvestrant: Fulvestrant: 250 mg IM Q 4 weeks
erlotinib: 150 mg PO QD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Either Complete Response or Partial Response</title>
          <description>evaluate response rate and the clinical benefit of fulvestrant alone or in combination with erlotinib</description>
          <population>Early termination due to a change in drug FDA approval. Outcome measures not computed on collected data because data would not be statistically relevant. No data analysis was completed. No data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fulvestrant Plus Placebo</title>
          <description>Fulvestrant: 250 mg IM Q 4 weeks
Placebo: 150 mg PO QD
Fulvestrant: 250 mg IM Q 4 weeks
Placebo: Placebo 150 mg PO QD</description>
        </group>
        <group group_id="E2">
          <title>Fulvestrant Plus Erlotinib</title>
          <description>Fulvestrant: 250 mg IM Q 4 weeks
Erlotinib: 150 mg PO QD
Fulvestrant: Fulvestrant: 250 mg IM Q 4 weeks
erlotinib: 150 mg PO QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>possible heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>fever of unknown origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>pulmonary embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>nausea/vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to a change in drug FDA approval. Outcome measures not computed because data would not be statistically relevant.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Beth Scanlan</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-686-8274</phone>
      <email>bscanlan@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

